[go: up one dir, main page]

WO2024118998A3 - Engineered anti-sars-cov-2 antibodies and methods of using the same - Google Patents

Engineered anti-sars-cov-2 antibodies and methods of using the same Download PDF

Info

Publication number
WO2024118998A3
WO2024118998A3 PCT/US2023/081959 US2023081959W WO2024118998A3 WO 2024118998 A3 WO2024118998 A3 WO 2024118998A3 US 2023081959 W US2023081959 W US 2023081959W WO 2024118998 A3 WO2024118998 A3 WO 2024118998A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
sars
clade
antigen
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/081959
Other languages
French (fr)
Other versions
WO2024118998A2 (en
Inventor
Elisabetta CAMERONI
Davide Corti
Chiara D'AVINO
Susannah Karen DAVIS
Anna Lowegard
Martin Anibal Orecchia
Dora PINTO
Matteo Samuele PIZZUTO
Christopher James Plummer
Martin James SCOTT
Gyorgy Snell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Glaxo Wellcome Uk Ltd
Vir Biotechnology Inc
Original Assignee
Humabs Biomed SA
Glaxo Wellcome Uk Ltd
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA, Glaxo Wellcome Uk Ltd, Vir Biotechnology Inc filed Critical Humabs Biomed SA
Publication of WO2024118998A2 publication Critical patent/WO2024118998A2/en
Publication of WO2024118998A3 publication Critical patent/WO2024118998A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, the presently disclosed antibodies are capable of binding to S proteins of multiple sarbecoviruses and/or neutralizing infection by multiple sarbecoviruses. In some embodiments, a sarbecovirus is from clade 1a, clade 1b, clade 2, or clade 3. In some embodiments, a sarbecovirus comprises a SARS-CoV-2, a SARS-CoV-2 G504D variant, a SARS-CoV delta variant, a SARS-CoV, or any combination thereof. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a sarbecovirus infection, such as a SARS-CoV-2 infection.
PCT/US2023/081959 2022-12-01 2023-11-30 Engineered anti-sars-cov-2 antibodies and methods of using the same Ceased WO2024118998A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263385748P 2022-12-01 2022-12-01
US63/385,748 2022-12-01

Publications (2)

Publication Number Publication Date
WO2024118998A2 WO2024118998A2 (en) 2024-06-06
WO2024118998A3 true WO2024118998A3 (en) 2024-07-11

Family

ID=89508964

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/081959 Ceased WO2024118998A2 (en) 2022-12-01 2023-11-30 Engineered anti-sars-cov-2 antibodies and methods of using the same

Country Status (1)

Country Link
WO (1) WO2024118998A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021211775A1 (en) * 2020-04-14 2021-10-21 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
WO2021247925A1 (en) * 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
WO2022204202A1 (en) * 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
MXPA02003456A (en) 1999-10-04 2002-10-23 Medicago Inc Method for regulating transcription of foreign genes in the presence of nitrogen.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
ATE492562T1 (en) 2003-09-24 2011-01-15 Kyowa Hakko Kirin Co Ltd RECOMBINANT ANTIBODY AGAINST HUMAN INSULIN-LIKE GROWTH FACTOR
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
MX2016008667A (en) 2013-12-30 2017-02-02 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof.
US11267899B2 (en) 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine Antibodies with functional domains in the elbow region
KR20250114570A (en) 2017-09-22 2025-07-29 우시 바이올로직스 아일랜드 리미티드 Novel bispecific polypeptide complexs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021211775A1 (en) * 2020-04-14 2021-10-21 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
WO2021247925A1 (en) * 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
WO2022204202A1 (en) * 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MATHIEU DONDELINGER ET AL: "Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition", FRONTIERS IN IMMUNOLOGY, vol. 9, 16 October 2018 (2018-10-16), pages 1 - 15, XP055572450, DOI: 10.3389/fimmu.2018.02278 *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 79, no. 6, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP002683593, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 *
TORTORICI M. ALEJANDRA ET AL: "Broad sarbecovirus neutralization by a human monoclonal antibody", NATURE, vol. 597, no. 7874, 2 September 2021 (2021-09-02), pages 103 - 108, XP055845075, Retrieved from the Internet <URL:https://www.nature.com/articles/s41586-021-03817-4.pdf> DOI: 10.1038/s41586-021-03817-4 *
WINKLER K ET AL: "Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, vol. 165, no. 8, 15 October 2000 (2000-10-15), pages 4505 - 4514, XP002579393, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2024118998A2 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
EP4245373A3 (en) Antibodies against sars-cov-2
PH12022500020A1 (en) Antibodies against sars-cov-2
BR112022015374A2 (en) ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USE THEREOF
BR112022020706A2 (en) ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF THEIR USE
WO2021173896A8 (en) Materials and methods for modulating an immune response
WO2008031133A3 (en) Borrelia antigens
WO2019165122A8 (en) Neutralizing antibodies to hiv-1 env and their use
MX2022013894A (en) Neutralizing antibodies that bind the sars-cov-2 s protein.
WO2022067269A3 (en) Antibodies against sars-cov-2
WO2022032003A3 (en) Anti-claudin 18.2 antibodies and uses thereof
WO2024191972A3 (en) Anti-lipocalin-2 antibodies and uses thereof
WO2023205239A3 (en) Dna therapeutic encoding an antibody or antigen binding fragment
WO2020057742A1 (en) Vaccine and antibody against clostidioides difficile toxin
WO2024118998A3 (en) Engineered anti-sars-cov-2 antibodies and methods of using the same
WO2022159839A8 (en) Monoclonal antibodies against coronaviruses and uses thereof
WO2023122659A3 (en) Conditionally activated antigen binding polypeptide complexes and methods of use thereof
EA202191658A1 (en) ANTIBODIES AGAINST HUMAN COMPLETE FACTOR C2B AND METHODS OF APPLICATION
ZA202404271B (en) Bispecific cd16a binders
WO2024194686A3 (en) Anti-phosphocholine antibodies and methods of use thereof
ZA202404272B (en) Bispecific cd16a binders
WO2024007013A3 (en) Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof
WO2023122647A3 (en) Methods for detecting or treating influenza infections
WO2024007012A3 (en) Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof
WO2025122587A3 (en) Anti-ly6k antibodies and methods of use
WO2023230445A3 (en) Broadly neutralizing antibodies against influenza neuraminidase

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23837479

Country of ref document: EP

Kind code of ref document: A2